Trial Condition(s):

Venous Thromboembolism

Xarelto for VTE prophylaxis after hip or knee arthroplasty (XAMOS)

Bayer Identifier:

13802

ClinicalTrials.gov Identifier:

NCT00831714

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The main goal is to provide additional information to the risk-benefit assessment of the drug.

Inclusion Criteria
- Female and male patients who will  undergo elective hip or knee arthroplasty.
Exclusion Criteria
- Exclusion criteria must be read in conjunction with the local product information.

Trial Summary

Enrollment Goal
19076
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Germany

Status
Completed
 
Locations

Investigative Site

Many Locations, United Kingdom

Status
Completed
 
Locations

Investigative Site

Many Locations, France

Status
Completed
 
Locations

Investigative Site

Many Locations, Italy

Status
Completed
 
Locations

Investigative Site

Many Locations, Canada

Status
Completed
 
Locations

Investigative Site

Many Locations, Sweden

Status
Completed
 
Locations

Investigative Site

Many Locations, Portugal

Status
Completed
 
Locations

Investigative Site

Many Locations, Hungary

Status
Completed
 
Locations

Investigative Site

Many Locations, Greece

Status
Completed
 
Locations

Investigative Site

Many Locations, Slovakia

Status
Completed
 
Locations

Investigative Site

Many Locations, South Korea

Status
Completed
 
Locations

Investigative Site

Many Locations, Hong Kong, China

Status
Completed
 
Locations

Investigative Site

Many Locations, Singapore

Status
Completed
 
Locations

Investigative Site

Many Locations, Latvia

Status
Completed
 
Locations

Investigative Site

Many Locations, Macedonia

Status
Completed
 
Locations

Investigative Site

Many Locations, Mexico

Status
Completed
 
Locations

Investigative Site

Many Locations, Spain

Status
Completed
 
Locations

Investigative Site

Many Locations, Belgium

Status
Completed
 
Locations

Investigative Site

Many Locations, Netherlands

Status
Completed
 
Locations

Investigative Site

Many Locations, Denmark

Status
Completed
 
Locations

Investigative Site

Many Locations, Czech Republic

Status
Completed
 
Locations

Investigative Site

Many Locations, Australia

Status
Completed
 
Locations

Investigative Site

Many Locations, Austria

Status
Completed
 
Locations

Investigative Site

Many Locations, China

Status
Completed
 
Locations

Investigative Site

Many Locations, Lithuania

Status
Completed
 
Locations

Investigative Site

Many Locations, Finland

Status
Completed
 
Locations

Investigative Site

Many Locations, Venezuela

Status
Completed
 
Locations

Investigative Site

Many Locations, Estonia

Status
Terminated
 
Locations

Investigative Site

Many Locations, Serbia

Status
Completed
 
Locations

Investigative Site

Many Locations, Cyprus

Status
Completed
 
Locations

Investigative Site

Many Locations, South Africa

Status
Terminated
 
Locations

Investigative Site

Many Locations, Norway

Status
Completed
 
Locations

Investigative Site

Many Locations, Chile

Status
Completed
 
Locations

Investigative Site

Many Locations, Colombia

Status
Completed
 
Locations

Investigative Site

Many Locations, Brazil

Status
Terminated
 
Locations

Investigative Site

Many Locations, Bosnia and Herzegovina

Status
Completed
 
Locations

Investigative Site

Many Locations, Lebanon

Status
Completed
 
Locations

Investigative Site

Many Locations, Philippines

Status
Completed
 
Locations

Investigative Site

Many Locations, Switzerland

Status
Completed
 
Locations

Investigative Site

Many Locations, United Arab Emirates

Status
Completed
 
Locations

Investigative Site

Many Locations, India

Status
Completed
 
Locations

Investigative Site

Many Locations, Vietnam

Status
Completed
 

Trial Design